HEP-1 (Gepon): Human Ezrin Peptide, NF-κB/IL-6 Axis Suppression, and Adaptive Immunity Amplification
Molecular Identity and Structural Architecture Ezrin Protein Origin and the HepReceptor Human ezrin is a member of the ERM (EzrinRadixinMoesin) family of proteins that function as linkers between the actin cytoskeleton and the plasma membrane. Ezrin exists in two distinct conformational states: a closed/inactive cytoplasmic form and an open/active submembrane form. The transition between these states is regulated by phosphorylation and is critical for the organisation of multiprotein cellsignalling complexes at the cell surface, including adhesion molecules, receptors, adaptor proteins, kinases, and cytoskeletal components. The 'Hepreceptor' refers to a surfaceexposed receptor transition conformation of ezrin present on the exterior surface of cell membranes. HEP1 was designed to mimic and bind to this receptor conformation. Critically, the molecular origin of HEP1 traces to the discovery by Dr Holms in the early 1990s that the amino acid sequence at the Cterminus of HIV gp120 mimics part of the Alpha domain of human ezrin. This molecular mimicry is mutationstable, indicating functional conservation, and provided the structural template for the development of HEP1. Sequence Characteristics and Physicochemical Properties The primary sequence of HEP1 is ThrGluLysLysArgArgGluThrValGluArgGluLysGlu (TEKKRRETVEREKE), corresponding to amino acids 324–337 of the human ezrin Alpha domain. The molecular formula is C₄H₁₃₂N₂₆O₂₇, with a molecular weight of approximately 1.7 kDa. The peptide adopts a 4turn alphahelical conformation and is highly charged due to the abundance of basic residues (Lys, Arg) and acidic residues (Glu), rendering it highly soluble in aqueous solution. HEP1 is stable at room temperature in solid form for at least two years and degrades at approximately 1% per month in aqueous solution, making it suitable for pharmaceutical formulation and storage. The active substance is inexpensive to manufacture, and the peptide is active on mucosal membrane surfaces, enabling nasal, sublingual, and topical administration routes in addition to injection. Mechanistic Rationale: Dual Immunomodulatory Action Ezrin Conformational Activation and Membrane Signalling Upon binding to the Hepreceptor conformation of ezrin on the exterior of cell membranes, HEP1 induces allosteric changes in the submembrane multiprotein complex, stimulating the transition from the closed/inactive to the open/active conformation of ezrin. This conformational shift results in enhanced receptor clustering and the organisation of membraneassociated cellsignalling complexes, triggering intracellular signalling cascades. The primary downstream pathway activated is the PKA (protein kinase A) CREB (cAMP response elementbinding protein) signalling axis, which plays a central role in both the antiinflammatory and immuneamplifying effects of HEP1. NFκB/IL6 Axis Suppression: Antiinflammatory Mechanism One of the most significant pharmacological properties of HEP1 is its capacity to suppress NFκBmediated chronic expression of proinflammatory cytokines. NFκB (nuclear factor kappalightchainenhancer of activated B cells) is a master transcriptional regulator of inflammation, controlling the expression of IL1β, IL6, IL8, and TNFα. Dysregulated NFκB activation underlies a broad spectrum of inflammatory and infectious diseases, from viral hepatitis and ulcerative colitis to cytokine storm in COVID19. HEP1 suppresses NFκB activation through the induction of PKA CREB signalling, which counteracts the RAGE (Receptor for Advanced Glycation Endproducts) / TLR4 (TollLike Receptor 4) proinflammatory feedback loop. In the context of SARSCoV2 infection, spike protein binding to mRAGE and TLR4 triggers hyperexpression of PKC, p38, NFκB, and IL6, establishing a selfsustaining inflammatory loop. HEP1 interrupts this loop by inducing PKA CREB signalling, thereby reducing IL6, IL8, and TNFα expression and attenuating the cytokine storm. "Ezrin peptides amplify adaptive immunity through the RANTES/CCL5 pathways that lead to cures of drug resistant infections due to bacteria, viruses, fungi and protozoans. Ezrin peptides simultaneously suppress chronic proinflammatory cytokine and chemokine signalling, leading to cures for chronic inflammatory disease." — Holms RD. Microbiol Immunol Pathol. 2024 RANTES/CCL5 Pathway: Adaptive Immunity Amplification In parallel with its antiinflammatory activity, HEP1 amplifies adaptive immunity through the RANTES/CCL5 (Regulated on Activation, Normal T Cell Expressed and Secreted / CC Motif Chemokine Ligand 5) chemokine pathway. RANTES/CCL5 is a critical chemokine that recruits T cells, NK cells, dendritic cells, and monocytes to sites of infection and inflammation, and plays a central role in the coordination of adaptive immune responses against viral pathogens. Evidence for this mechanism emerged from blood results in a Long COVID vaccine injury patient treated with RepG3 (a derivative of HEP1), which demonstrated enhanced RANTES/CCL5 e
For research use only. Not for human consumption.